Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HP-1050
- Development stage
- Phase 1
- Lead developer
- Noven Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
**HP-1050** is an investigational transdermal contraceptive system developed by Noven Pharmaceuticals. It has been evaluated in a randomized, evaluator-blinded Phase 1 study in healthy adult female volunteers that compared cumulative skin irritation and sensitization with the norelgestromin/ethinyl estradiol patch Xulane. Publicly available trial information does not disclose HP-1050's active ingredient composition, specific pharmacologic targets, or a commercial brand name.
- Other names
- HP-1050 PatchHP1050 PatchHP 1050 PatchHP-1050 Transdermal SystemHP1050 Transdermal SystemHP 1050 Transdermal System
02
Targets
ER (Estrogen receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on HP-1050.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HP-1050.